Microbiota Division, Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.
Gut Microbes. 2023 Jan-Dec;15(1):2236364. doi: 10.1080/19490976.2023.2236364.
Colorectal cancer (CRC) is the third most common malignant tumor worldwide. The incidence and mortality rates of CRC have been increasing in China, possibly due to economic development, lifestyle, and dietary changes. Evidence suggests that gut microbiota plays an essential role in the tumorigenesis of CRC. Gut dysbiosis, specific pathogenic microbes, metabolites, virulence factors, and microbial carcinogenic mechanisms contribute to the initiation and progression of CRC. Gut microbiota biomarkers have potential translational applications in CRC screening and early diagnosis. Gut microbiota-related interventions could improve anti-tumor therapy's efficacy and severe intestinal toxic effects. Chinese researchers have made many achievements in the relationship between gut microbiota and CRC, although some challenges remain. This review summarizes the current evidence from China on the role of gut microbiota in CRC, mainly including the gut microbiota characteristics, especially and , which have been identified to be enriched in CRC patients; microbial pathogens such as and enterotoxigenic , and , which Chinese scientists have extensively studied; diagnostic biomarkers especially ; therapeutic effects, including microecological agents represented by certain strains, fecal microbiota transplantation, and traditional Chinese medicines such as Berberine and Curcumin. More efforts should be focused on exploring the underlying mechanisms of microbial pathogenesis of CRC and providing novel gut microbiota-related therapeutic and preventive strategies.
结直肠癌(CRC)是全球第三大常见恶性肿瘤。中国 CRC 的发病率和死亡率呈上升趋势,这可能与经济发展、生活方式和饮食变化有关。有证据表明,肠道微生物群在 CRC 的发生发展中起重要作用。肠道微生态失调、特定的致病性微生物、代谢物、毒力因子和微生物致癌机制都有助于 CRC 的起始和进展。肠道微生物群生物标志物在 CRC 的筛查和早期诊断中有潜在的转化应用。与肠道微生物群相关的干预措施可以提高抗肿瘤治疗的疗效和严重的肠道毒性作用。中国研究人员在肠道微生物群与 CRC 的关系方面取得了许多成就,尽管仍存在一些挑战。本综述总结了目前中国关于肠道微生物群在 CRC 中的作用的证据,主要包括肠道微生物群的特征,特别是在 CRC 患者中被发现丰富的 和 ;中国科学家广泛研究的微生物病原体,如 和 ;诊断生物标志物,特别是 ;治疗效果,包括以某些 菌株为代表的微生态制剂、粪便微生物移植和黄连素、姜黄素等中药。应进一步努力探索 CRC 微生物发病机制的潜在机制,并提供新的肠道微生物群相关的治疗和预防策略。